Janet Jill Hopkins Sells 11,822 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) Stock

Aura Biosciences, Inc. (NASDAQ:AURA) insider Janet Jill Hopkins sold 11,822 shares of the company’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $9.36, for a total transaction of $110,653.92. Following the transaction, the insider now owns 151,693 shares of the company’s stock, valued at approximately $1,419,846.48. The trade was a 7.23 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Aura Biosciences Price Performance

Aura Biosciences stock opened at $8.92 on Wednesday. Aura Biosciences, Inc. has a 12-month low of $6.63 and a 12-month high of $12.38. The stock has a market capitalization of $445.55 million, a PE ratio of -5.16 and a beta of 0.33. The firm has a 50 day simple moving average of $9.85 and a 200-day simple moving average of $8.55.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.02. On average, analysts forecast that Aura Biosciences, Inc. will post -1.69 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on AURA. BTIG Research boosted their price target on Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a research note on Friday, October 18th. Lifesci Capital upgraded Aura Biosciences to a “strong-buy” rating in a report on Monday, September 9th. Evercore ISI raised shares of Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 16th. HC Wainwright reissued a “buy” rating and set a $22.00 price target on shares of Aura Biosciences in a research report on Thursday, November 14th. Finally, Cowen reissued a “buy” rating on shares of Aura Biosciences in a research note on Friday, October 18th. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $23.00.

Institutional Trading of Aura Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. American Century Companies Inc. acquired a new position in shares of Aura Biosciences during the second quarter worth approximately $119,000. American International Group Inc. raised its position in Aura Biosciences by 27.4% in the first quarter. American International Group Inc. now owns 17,579 shares of the company’s stock worth $138,000 after purchasing an additional 3,782 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Aura Biosciences in the 1st quarter worth approximately $144,000. SG Americas Securities LLC acquired a new stake in shares of Aura Biosciences in the 3rd quarter valued at $169,000. Finally, Rhumbline Advisers boosted its position in Aura Biosciences by 39.6% in the second quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock valued at $480,000 after buying an additional 18,011 shares in the last quarter. Institutional investors and hedge funds own 96.75% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.